Orphazyme A/S(NASDAQ:ORPH)announces regulatory updates for arimoclomol, for which it is seeking marketing authorization in both Europe and U.S. for the treatment of Niemann-Pick disease Type C. Shares...
网页链接Orphazyme A/S(NASDAQ:ORPH)announces regulatory updates for arimoclomol, for which it is seeking marketing authorization in both Europe and U.S. for the treatment of Niemann-Pick disease Type C. Shares...
网页链接
精彩评论